Drug Profile


Alternative Names: OCV-103/104; OCV-103/OCV-104; OCV-104/103; OCV-104/OCV-103; OCV-C02; OTS 103/104

Latest Information Update: 23 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OncoTherapy Science
  • Developer OncoTherapy Science; Otsuka Pharmaceutical
  • Class Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Colorectal cancer

Most Recent Events

  • 20 Nov 2017 OCV C02 is still in phase I trials for Colorectal cancer (Late-stage disease, Second-line therapy or greater) in Japan (Parenteral, Injection) (Otsuka Pharmaceutical pipeline, November 2017)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Colorectal-cancer(Late-stage disease, Second-line therapy or greater) in Japan (Parenteral, Injection)
  • 18 Jan 2017 Efficacy, safety and immunological data from a phase I trial in Colorectal cancer released by Otsuka Pharmaceutical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top